Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Nov 12, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at whether a substance called isomaltooligosaccharides (IMO) can help protect patients with liver cirrhosis from the harmful effects of bacteria moving from the gut into the bloodstream. The researchers want to see how taking IMO affects levels of a specific marker called LPS, which can indicate bacterial translocation. The trial is currently recruiting patients aged 18 to 75 who have cirrhosis and are experiencing fluid buildup in the abdomen, known as ascites.

To participate, you must meet certain criteria, such as having a specific level of LPS in your blood. However, the study is not open to pregnant or breastfeeding individuals, those with active infections, or patients with severe liver complications. If you join the trial, you will be monitored closely while taking the IMO supplement, and the information gathered will help researchers understand how it affects your health. This could be an important step in finding better treatments for people with liver cirrhosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age from 18-75.
• • Cirrhotic patients.
• • Decompensation event: ascites.
• • LPS\>0.45EU/ml.
• Exclusion Criteria:
• • Pregnant or breast-feeding.
• • Active bacterial or fungal infection.
• • Other decompensations: Hepatic encephalopathy, gastroesophageal varices and hemorrhage.
• • Diagnosis of EASL-ACLF.
• • Diarrhea.
• • Malignancy.
• • Anticipated short survival time.
• • Adverse reactions or allergies to oral carbohydrate preparations.
• • Substance abuse or addiction.
• • Severe extrahepatic diseases (e.g. patients with CKD-5 stage, severe cardiopulmonary dysfunction, and psychiatric disorders).
• • Be immunosuppressed or immunodeficient states and the use of immunoglobulins or other immune-boosting conditions.
• • Be unsuitable for participating in this trial.
• • Participated in any drug trial within the past month
• • History of antibacterial or fungal use within 1 week prior to screening